Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls

John B Christoforidis, Zhiliang Xie, Angela Jiang, Jillian Wang, Cedric Pratt, Anne Gemensky-Metzler, Mahmoud Abdel-Rasoul, Sashwati Roy, Zhongfa Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To determine serum level differences of intravitreally-placed bevacizumab after vitrectomy and lensectomy-vitrectomy and to compare these with non-operated eyes in a rabbit model. Methods: Five Dutch-belted rabbits underwent pars plana vitrectomy (PPV), five rabbits underwent pars plana lensectomy (PPL) and five rabbits served as non-surgical controls. Twelve days following the surgical procedures, each operated eye underwent an intravitreal injection consisting of 1.25 mg/0.05 mL bevacizumab. Serum levels from each rabbit were drawn on days 2, 4, 7, 10, 14, 21, 28 and 35 and were measured with ELISA immunoassay. Results: The average peak serum concentration (Cmax) was highest for the PPL group (11.33 μg ± 3.48 mL), and was similar between the PPV (5.35 μg ± 2.69 mL) and non-surgical control groups (5.35 μg ± 0.69 mL). The average time to maximal plasma concentration (Tmax) in days was earliest for the PPL group (2.8 ± 0.47), followed by the PPV (5.6 ± 0.84) and non-surgical control groups (6.4 ± 0.71). The PPL group had higher serum levels than the other two groups until day 7 that was significant only at day 2 (p < 0.0001). After day 4, there were no significant differences or trends between any of the three groups. The half-life (T1/2) was fastest for the PPL group (1.41 ± 0.21 d) followed by the PPV (2.80 ± 3.35 d) and non-surgical control groups (6.69 ± 10.4 d). Conclusions: Serum bevacizumab levels were initially elevated following lensectomy and vitrectomy compared to non-surgical eyes following intravitreal injection. The half-life of bevacizumab was prolonged in non-surgical eyes presumably due to a slower release from the vitreous cavity.

Original languageEnglish (US)
Pages (from-to)761-766
Number of pages6
JournalCurrent Eye Research
Volume38
Issue number7
DOIs
StatePublished - 2013

Fingerprint

Temazepam
Vitrectomy
Serum
Rabbits
Intravitreal Injections
Control Groups
Half-Life
Bevacizumab
Immunoassay
Enzyme-Linked Immunosorbent Assay

Keywords

  • Bevacizumab
  • Lensectomy
  • Pharmacokinetics
  • Serum
  • Vascular endothelial growth factor
  • Vitrectomy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls. / Christoforidis, John B; Xie, Zhiliang; Jiang, Angela; Wang, Jillian; Pratt, Cedric; Gemensky-Metzler, Anne; Abdel-Rasoul, Mahmoud; Roy, Sashwati; Liu, Zhongfa.

In: Current Eye Research, Vol. 38, No. 7, 2013, p. 761-766.

Research output: Contribution to journalArticle

Christoforidis, JB, Xie, Z, Jiang, A, Wang, J, Pratt, C, Gemensky-Metzler, A, Abdel-Rasoul, M, Roy, S & Liu, Z 2013, 'Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls', Current Eye Research, vol. 38, no. 7, pp. 761-766. https://doi.org/10.3109/02713683.2013.763988
Christoforidis, John B ; Xie, Zhiliang ; Jiang, Angela ; Wang, Jillian ; Pratt, Cedric ; Gemensky-Metzler, Anne ; Abdel-Rasoul, Mahmoud ; Roy, Sashwati ; Liu, Zhongfa. / Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls. In: Current Eye Research. 2013 ; Vol. 38, No. 7. pp. 761-766.
@article{fff7f7d7d0804e10a110e8a2e290a626,
title = "Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls",
abstract = "Purpose: To determine serum level differences of intravitreally-placed bevacizumab after vitrectomy and lensectomy-vitrectomy and to compare these with non-operated eyes in a rabbit model. Methods: Five Dutch-belted rabbits underwent pars plana vitrectomy (PPV), five rabbits underwent pars plana lensectomy (PPL) and five rabbits served as non-surgical controls. Twelve days following the surgical procedures, each operated eye underwent an intravitreal injection consisting of 1.25 mg/0.05 mL bevacizumab. Serum levels from each rabbit were drawn on days 2, 4, 7, 10, 14, 21, 28 and 35 and were measured with ELISA immunoassay. Results: The average peak serum concentration (Cmax) was highest for the PPL group (11.33 μg ± 3.48 mL), and was similar between the PPV (5.35 μg ± 2.69 mL) and non-surgical control groups (5.35 μg ± 0.69 mL). The average time to maximal plasma concentration (Tmax) in days was earliest for the PPL group (2.8 ± 0.47), followed by the PPV (5.6 ± 0.84) and non-surgical control groups (6.4 ± 0.71). The PPL group had higher serum levels than the other two groups until day 7 that was significant only at day 2 (p < 0.0001). After day 4, there were no significant differences or trends between any of the three groups. The half-life (T1/2) was fastest for the PPL group (1.41 ± 0.21 d) followed by the PPV (2.80 ± 3.35 d) and non-surgical control groups (6.69 ± 10.4 d). Conclusions: Serum bevacizumab levels were initially elevated following lensectomy and vitrectomy compared to non-surgical eyes following intravitreal injection. The half-life of bevacizumab was prolonged in non-surgical eyes presumably due to a slower release from the vitreous cavity.",
keywords = "Bevacizumab, Lensectomy, Pharmacokinetics, Serum, Vascular endothelial growth factor, Vitrectomy",
author = "Christoforidis, {John B} and Zhiliang Xie and Angela Jiang and Jillian Wang and Cedric Pratt and Anne Gemensky-Metzler and Mahmoud Abdel-Rasoul and Sashwati Roy and Zhongfa Liu",
year = "2013",
doi = "10.3109/02713683.2013.763988",
language = "English (US)",
volume = "38",
pages = "761--766",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls

AU - Christoforidis, John B

AU - Xie, Zhiliang

AU - Jiang, Angela

AU - Wang, Jillian

AU - Pratt, Cedric

AU - Gemensky-Metzler, Anne

AU - Abdel-Rasoul, Mahmoud

AU - Roy, Sashwati

AU - Liu, Zhongfa

PY - 2013

Y1 - 2013

N2 - Purpose: To determine serum level differences of intravitreally-placed bevacizumab after vitrectomy and lensectomy-vitrectomy and to compare these with non-operated eyes in a rabbit model. Methods: Five Dutch-belted rabbits underwent pars plana vitrectomy (PPV), five rabbits underwent pars plana lensectomy (PPL) and five rabbits served as non-surgical controls. Twelve days following the surgical procedures, each operated eye underwent an intravitreal injection consisting of 1.25 mg/0.05 mL bevacizumab. Serum levels from each rabbit were drawn on days 2, 4, 7, 10, 14, 21, 28 and 35 and were measured with ELISA immunoassay. Results: The average peak serum concentration (Cmax) was highest for the PPL group (11.33 μg ± 3.48 mL), and was similar between the PPV (5.35 μg ± 2.69 mL) and non-surgical control groups (5.35 μg ± 0.69 mL). The average time to maximal plasma concentration (Tmax) in days was earliest for the PPL group (2.8 ± 0.47), followed by the PPV (5.6 ± 0.84) and non-surgical control groups (6.4 ± 0.71). The PPL group had higher serum levels than the other two groups until day 7 that was significant only at day 2 (p < 0.0001). After day 4, there were no significant differences or trends between any of the three groups. The half-life (T1/2) was fastest for the PPL group (1.41 ± 0.21 d) followed by the PPV (2.80 ± 3.35 d) and non-surgical control groups (6.69 ± 10.4 d). Conclusions: Serum bevacizumab levels were initially elevated following lensectomy and vitrectomy compared to non-surgical eyes following intravitreal injection. The half-life of bevacizumab was prolonged in non-surgical eyes presumably due to a slower release from the vitreous cavity.

AB - Purpose: To determine serum level differences of intravitreally-placed bevacizumab after vitrectomy and lensectomy-vitrectomy and to compare these with non-operated eyes in a rabbit model. Methods: Five Dutch-belted rabbits underwent pars plana vitrectomy (PPV), five rabbits underwent pars plana lensectomy (PPL) and five rabbits served as non-surgical controls. Twelve days following the surgical procedures, each operated eye underwent an intravitreal injection consisting of 1.25 mg/0.05 mL bevacizumab. Serum levels from each rabbit were drawn on days 2, 4, 7, 10, 14, 21, 28 and 35 and were measured with ELISA immunoassay. Results: The average peak serum concentration (Cmax) was highest for the PPL group (11.33 μg ± 3.48 mL), and was similar between the PPV (5.35 μg ± 2.69 mL) and non-surgical control groups (5.35 μg ± 0.69 mL). The average time to maximal plasma concentration (Tmax) in days was earliest for the PPL group (2.8 ± 0.47), followed by the PPV (5.6 ± 0.84) and non-surgical control groups (6.4 ± 0.71). The PPL group had higher serum levels than the other two groups until day 7 that was significant only at day 2 (p < 0.0001). After day 4, there were no significant differences or trends between any of the three groups. The half-life (T1/2) was fastest for the PPL group (1.41 ± 0.21 d) followed by the PPV (2.80 ± 3.35 d) and non-surgical control groups (6.69 ± 10.4 d). Conclusions: Serum bevacizumab levels were initially elevated following lensectomy and vitrectomy compared to non-surgical eyes following intravitreal injection. The half-life of bevacizumab was prolonged in non-surgical eyes presumably due to a slower release from the vitreous cavity.

KW - Bevacizumab

KW - Lensectomy

KW - Pharmacokinetics

KW - Serum

KW - Vascular endothelial growth factor

KW - Vitrectomy

UR - http://www.scopus.com/inward/record.url?scp=84878495127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878495127&partnerID=8YFLogxK

U2 - 10.3109/02713683.2013.763988

DO - 10.3109/02713683.2013.763988

M3 - Article

C2 - 23548066

AN - SCOPUS:84878495127

VL - 38

SP - 761

EP - 766

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 7

ER -